Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Identification of traits and functional connectivity-based neurotraits of chronic pain.

Vachon-Presseau E, Berger SE, Abdullah TB, Griffith JW, Schnitzer TJ, Apkarian AV.

PLoS Biol. 2019 Aug 20;17(8):e3000349. doi: 10.1371/journal.pbio.3000349. eCollection 2019 Aug.

2.

Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.

Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM.

JAMA. 2019 Jul 2;322(1):37-48. doi: 10.1001/jama.2019.8044.

3.

The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP.

Arthritis Rheumatol. 2019 Nov;71(11):1824-1834. doi: 10.1002/art.41012. Epub 2019 Sep 20.

4.

Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density.

Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB, Schnitzer TJ.

Spinal Cord. 2019 Oct;57(10):832-842. doi: 10.1038/s41393-019-0303-3. Epub 2019 Jun 4.

PMID:
31164732
5.

Deconstructing biomarkers for chronic pain: context- and hypothesis-dependent biomarker types in relation to chronic pain.

Reckziegel D, Vachon-Presseau E, Petre B, Schnitzer TJ, Baliki MN, Apkarian AV.

Pain. 2019 May;160 Suppl 1:S37-S48. doi: 10.1097/j.pain.0000000000001529.

PMID:
31008848
6.

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.

Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR.

J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

7.

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.

Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):976-980. doi: 10.3899/jrheum.181066. Epub 2019 Mar 1.

PMID:
30824657
8.

A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.

Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, Wang L, Feng S, Conaghan PG, Berenbaum F, Pelletier JP, Martel-Pelletier J, Vaeterlein O, Kaeley GS, Liu W, Kosloski MP, Levy G, Zhang L, Medema JK, Levesque MC.

Arthritis Rheumatol. 2019 Jul;71(7):1056-1069. doi: 10.1002/art.40840. Epub 2019 Jun 7.

9.

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Dodd S, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):981-989. doi: 10.3899/jrheum.181194. Epub 2019 Jan 15.

10.

Bone fragility after spinal cord injury: reductions in stiffness and bone mineral at the distal femur and proximal tibia as a function of time.

Haider IT, Lobos SM, Simonian N, Schnitzer TJ, Edwards WB.

Osteoporos Int. 2018 Dec;29(12):2703-2715. doi: 10.1007/s00198-018-4733-0. Epub 2018 Oct 17.

11.

CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.

Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, Deeg MA, Raddad E, Xiao N, de la Peña A, Kivitz AJ, Schnitzer TJ.

Osteoarthritis Cartilage. 2018 Dec;26(12):1609-1618. doi: 10.1016/j.joca.2018.08.019. Epub 2018 Sep 18.

12.

Brain and psychological determinants of placebo pill response in chronic pain patients.

Vachon-Presseau E, Berger SE, Abdullah TB, Huang L, Cecchi GA, Griffith JW, Schnitzer TJ, Apkarian AV.

Nat Commun. 2018 Sep 12;9(1):3397. doi: 10.1038/s41467-018-05859-1.

13.

Effects of Teriparatide and Vibration on Bone Mass and Bone Strength in People with Bone Loss and Spinal Cord Injury: A Randomized, Controlled Trial.

Edwards WB, Simonian N, Haider IT, Anschel AS, Chen D, Gordon KE, Gregory EK, Kim KH, Parachuri R, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2018 Oct;33(10):1729-1740. doi: 10.1002/jbmr.3525. Epub 2018 Jun 28.

14.

Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study.

McAlindon TE, Schmidt U, Bugarin D, Abrams S, Geib T, DeGryse RE, Kim K, Schnitzer TJ.

Osteoarthritis Cartilage. 2018 Oct;26(10):1291-1299. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.

15.

Inferring distinct mechanisms in the absence of subjective differences: Placebo and centrally acting analgesic underlie unique brain adaptations.

Tétreault P, Baliki MN, Baria AT, Bauer WR, Schnitzer TJ, Apkarian AV.

Hum Brain Mapp. 2018 May;39(5):2210-2223. doi: 10.1002/hbm.23999. Epub 2018 Feb 7.

16.

Hippocampal morphology mediates biased memories of chronic pain.

Berger SE, Vachon-Presseau É, Abdullah TB, Baria AT, Schnitzer TJ, Apkarian AV.

Neuroimage. 2018 Feb 1;166:86-98. doi: 10.1016/j.neuroimage.2017.10.030. Epub 2017 Nov 6.

17.

Tanezumab in the treatment of chronic musculoskeletal conditions.

Jayabalan P, Schnitzer TJ.

Expert Opin Biol Ther. 2017 Feb;17(2):245-254. doi: 10.1080/14712598.2017.1271873. Epub 2016 Dec 25. Review.

PMID:
27936977
18.

A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain.

Schnitzer TJ, Torbey S, Herrmann K, Kaushal G, Yeasted R, Vania Apkarian A.

Mol Pain. 2016 Nov 15;12. pii: 1744806916678627. Print 2016.

19.

Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials.

Tétreault P, Mansour A, Vachon-Presseau E, Schnitzer TJ, Apkarian AV, Baliki MN.

PLoS Biol. 2016 Oct 27;14(10):e1002570. doi: 10.1371/journal.pbio.1002570. eCollection 2016 Oct.

20.

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Aug 30;68(9):981-2. doi: 10.1016/j.jacc.2016.06.008. No abstract available.

21.

Corticolimbic anatomical characteristics predetermine risk for chronic pain.

Vachon-Presseau E, Tétreault P, Petre B, Huang L, Berger SE, Torbey S, Baria AT, Mansour AR, Hashmi JA, Griffith JW, Comasco E, Schnitzer TJ, Baliki MN, Apkarian AV.

Brain. 2016 Jul;139(Pt 7):1958-70. doi: 10.1093/brain/aww100. Epub 2016 May 5.

22.

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL; COGENT Investigators.

Am J Med. 2016 Sep;129(9):1002-5. doi: 10.1016/j.amjmed.2016.03.042. Epub 2016 Apr 30.

PMID:
27143321
23.

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21.

24.

The Emotional Brain as a Predictor and Amplifier of Chronic Pain.

Vachon-Presseau E, Centeno MV, Ren W, Berger SE, Tétreault P, Ghantous M, Baria A, Farmer M, Baliki MN, Schnitzer TJ, Apkarian AV.

J Dent Res. 2016 Jun;95(6):605-12. doi: 10.1177/0022034516638027. Epub 2016 Mar 10. Review.

25.

Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results of a Randomized, Placebo-Controlled Pilot Trial.

Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D.

PM R. 2016 Sep;8(9):833-43. doi: 10.1016/j.pmrj.2016.01.012. Epub 2016 Jan 30.

PMID:
26828618
26.

Bone Imaging and Fracture Risk after Spinal Cord Injury.

Edwards WB, Schnitzer TJ.

Curr Osteoporos Rep. 2015 Oct;13(5):310-7. doi: 10.1007/s11914-015-0288-6. Review.

PMID:
26277792
27.

The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL.

Aliment Pharmacol Ther. 2015 Aug;42(3):365-74. doi: 10.1111/apt.13260. Epub 2015 May 29.

28.

OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.

Losina E, Ranstam J, Collins JE, Schnitzer TJ, Katz JN.

Osteoarthritis Cartilage. 2015 May;23(5):677-85. doi: 10.1016/j.joca.2015.03.011. Review.

29.

Reduction in Torsional Stiffness and Strength at the Proximal Tibia as a Function of Time Since Spinal Cord Injury.

Edwards WB, Simonian N, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2015 Aug;30(8):1422-30. doi: 10.1002/jbmr.2474. Epub 2015 May 21.

30.

A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.

Schnitzer TJ, Marks JA.

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S8-17. doi: 10.1016/j.joca.2014.10.003. Review.

31.

Smoking increases risk of pain chronification through shared corticostriatal circuitry.

Petre B, Torbey S, Griffith JW, De Oliveira G, Herrmann K, Mansour A, Baria AT, Baliki MN, Schnitzer TJ, Apkarian AV.

Hum Brain Mapp. 2015 Feb;36(2):683-94. doi: 10.1002/hbm.22656. Epub 2014 Oct 12.

32.

Dual energy X-ray absorptiometry of the knee in spinal cord injury: methodology and correlation with quantitative computed tomography.

McPherson JG, Edwards WB, Prasad A, Troy KL, Griffith JW, Schnitzer TJ.

Spinal Cord. 2014 Nov;52(11):821-5. doi: 10.1038/sc.2014.122. Epub 2014 Jul 15.

PMID:
25023861
33.

Reduction in proximal femoral strength in patients with acute spinal cord injury.

Edwards WB, Schnitzer TJ, Troy KL.

J Bone Miner Res. 2014 Sep;29(9):2074-9. doi: 10.1002/jbmr.2227.

34.

Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.

Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM.

Ann Rheum Dis. 2015 Jun;74(6):1202-11. doi: 10.1136/annrheumdis-2013-204905. Epub 2014 Mar 13.

PMID:
24625625
35.

The mechanical consequence of actual bone loss and simulated bone recovery in acute spinal cord injury.

Edwards WB, Schnitzer TJ, Troy KL.

Bone. 2014 Mar;60:141-7. doi: 10.1016/j.bone.2013.12.012. Epub 2013 Dec 17.

36.

Reorganization of hippocampal functional connectivity with transition to chronic back pain.

Mutso AA, Petre B, Huang L, Baliki MN, Torbey S, Herrmann KM, Schnitzer TJ, Apkarian AV.

J Neurophysiol. 2014 Mar;111(5):1065-76. doi: 10.1152/jn.00611.2013. Epub 2013 Dec 11.

37.

Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury.

Edwards WB, Schnitzer TJ, Troy KL.

Osteoporos Int. 2014 Mar;25(3):1005-15. doi: 10.1007/s00198-013-2557-5. Epub 2013 Nov 5.

PMID:
24190426
38.

Towards a mechanism-based approach to pain management in osteoarthritis.

Malfait AM, Schnitzer TJ.

Nat Rev Rheumatol. 2013 Nov;9(11):654-64. doi: 10.1038/nrrheum.2013.138. Epub 2013 Sep 17. Review.

39.

Brain white matter structural properties predict transition to chronic pain.

Mansour AR, Baliki MN, Huang L, Torbey S, Herrmann KM, Schnitzer TJ, Apkarian AV.

Pain. 2013 Oct;154(10):2160-8. doi: 10.1016/j.pain.2013.06.044.

40.

Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits.

Hashmi JA, Baliki MN, Huang L, Baria AT, Torbey S, Hermann KM, Schnitzer TJ, Apkarian AV.

Brain. 2013 Sep;136(Pt 9):2751-68. doi: 10.1093/brain/awt211.

41.

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C.

Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

42.

Torsional stiffness and strength of the proximal tibia are better predicted by finite element models than DXA or QCT.

Edwards WB, Schnitzer TJ, Troy KL.

J Biomech. 2013 Jun 21;46(10):1655-62. doi: 10.1016/j.jbiomech.2013.04.016. Epub 2013 May 13.

43.

Effect of parathyroid hormone combined with gait training on bone density and bone architecture in people with chronic spinal cord injury.

Gordon KE, Wald MJ, Schnitzer TJ.

PM R. 2013 Aug;5(8):663-71. doi: 10.1016/j.pmrj.2013.03.032. Epub 2013 Apr 1.

PMID:
23558091
44.

Bone mineral loss at the proximal femur in acute spinal cord injury.

Edwards WB, Schnitzer TJ, Troy KL.

Osteoporos Int. 2013 Sep;24(9):2461-9. doi: 10.1007/s00198-013-2323-8. Epub 2013 Mar 7.

PMID:
23468075
45.

Intra-articular hylastan versus steroid for knee osteoarthritis.

Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Waddell D, Tahir H, Hammond A, Goupille P, Sanson BJ, Elkins C, Bailleul F.

Knee Surg Sports Traumatol Arthrosc. 2014 Jul;22(7):1684-92. doi: 10.1007/s00167-013-2438-7. Epub 2013 Feb 16.

PMID:
23417236
46.

Brain networks predicting placebo analgesia in a clinical trial for chronic back pain.

Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV.

Pain. 2012 Dec;153(12):2393-402. doi: 10.1016/j.pain.2012.08.008. Epub 2012 Sep 15.

47.

Bone mineral density in patients with stroke: relationship with motor impairment and functional mobility.

Schnitzer TJ, Harvey RL, Nack SH, Supanwanid P, Maskala-Streff L, Roth E.

Top Stroke Rehabil. 2012 Sep-Oct;19(5):436-43. doi: 10.1310/tsr1905-436.

PMID:
22982831
48.

Calcaneal quantitative ultrasound compared with hip and femoral neck dual-energy x-ray absorptiometry in people with a spinal cord injury.

Schnitzer TJ, Wysocki N, Barkema D, Griffith J, Lent V, Romba M, Welbel R, Bhuva S, Manyam B, Linn S.

PM R. 2012 Oct;4(10):748-55. doi: 10.1016/j.pmrj.2012.05.011. Epub 2012 Jul 28.

PMID:
22841967
49.

Corticostriatal functional connectivity predicts transition to chronic back pain.

Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, Fields HL, Apkarian AV.

Nat Neurosci. 2012 Jul 1;15(8):1117-9. doi: 10.1038/nn.3153.

50.

Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension.

Schnitzer TJ, Pelletier JP, Haselwood DM, Ellison WT, Ervin JE, Gordon RD, Lisse JR, Archambault WT, Sampson AR, Fezatte HB, Phillips SB, Bernstein JE.

J Rheumatol. 2012 Mar;39(3):610-20. doi: 10.3899/jrheum.110192. Epub 2011 Nov 15.

PMID:
22089461

Supplemental Content

Loading ...
Support Center